MedImmune Turns To Venture Philanthropy For Cancer ImmunoRx Combination Trials
This article was originally published in The Pink Sheet Daily
MedImmune and two non-profit research organizations are collaborating on clinical trials that explore the tricky world of combinations of novel cancer immunotherapies, including three MedImmune compounds in different stages of development.
You may also be interested in...
Developments in off-label enforcement and scrutiny of economic superiority claims, new approaches to R&D, and biosimilars are among issues that captured readers’ attention last year.
Autism Speaks, an advocacy group that has devoted nearly $200 million to basic research on autism spectrum disorders since 2005, is spinning out a venture arm called Delivering Scientific Innovation for Autism to fund efforts by the for-profit sector. The amount of funding involved is “not insignificant,” said Robert Ring, who left Pfizer in 2011 to spearhead the move into the transitional space.
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.